Spartalizumab
Modify Date: 2024-01-05 14:47:01
Spartalizumab structure
|
Common Name | Spartalizumab | ||
|---|---|---|---|---|
| CAS Number | 1935694-88-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SpartalizumabSpartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC)[1]. |
| Name | Spartalizumab |
|---|
| Description | Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC)[1]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |